KAHR Medical
Tel Aviv, Israel· Est.
Israeli biotech delivering CRISPR‑derived gene‑editing and mRNA therapeutics for rare diseases and oncology.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $150M
AI Company Overview
Israeli biotech delivering CRISPR‑derived gene‑editing and mRNA therapeutics for rare diseases and oncology.
Genetic DisordersOncology
Technology Platform
Proprietary CRISPR‑derived high‑fidelity nuclease (KAHR‑Edit) combined with lipid nanoparticle mRNA delivery (KAHR‑RNA) for in‑vivo gene editing and therapeutic protein expression.
Opportunities
First‑in‑class in‑vivo CRISPR therapies for rare diseases and mRNA‑encoded checkpoint inhibitors could open high‑value markets and attract partnership deals.
Risk Factors
Technical challenges in efficient in‑vivo delivery, regulatory uncertainty for gene‑editing therapies, and competition from larger biotech firms.
Competitive Landscape
Competes with pure CRISPR firms (Editas, CRISPR Therapeutics) and mRNA companies (Moderna, BioNTech); differentiation lies in the integrated gene‑editing plus mRNA delivery platform.